Literature DB >> 17352723

Expression of CCR5 in graft-versus-host disease (GVHD) of the skin: immunohistochemical staining of 38 cases.

Naoko I Morita1, Yumi Matsumura, Kazumasa Morita, Yoshiki Miyachi.   

Abstract

To ascertain the involvement of CCR5 in prolongation of graft-versus-host disease (GVHD), we performed immunohistochemical staining of CCR5 in 38 GVHD samples (23 acute and 15 chronic). A total of seven out of 15 cases of chronic GVHD were positive for CCR5; however, only two out of 23 in acute GVHD were positive for CCR5. In three cases, expression of CCR5 in infiltrating lymphocytes was negative in the acute phase, but positive in the chronic phase of GVHD. These findings suggest that the immunopathological mechanism that differentiates between acute and chronic GVHD is a CCR5-mediated immunoreaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17352723     DOI: 10.1111/j.1346-8138.2007.00263.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  3 in total

1.  An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Authors:  Edouard Forcade; Katelyn Paz; Ryan Flynn; Brad Griesenauer; Tohti Amet; Wei Li; Liangyi Liu; Giorgos Bakoyannis; Di Jiang; Hong Wei Chu; Mercedes Lobera; Jianfei Yang; David S Wilkes; Jing Du; Kate Gartlan; Geoffrey R Hill; Kelli Pa MacDonald; Eduardo L Espada; Patrick Blanco; Jonathan S Serody; John Koreth; Corey S Cutler; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Sophie Paczesny; Bruce R Blazar
Journal:  JCI Insight       Date:  2017-06-15

2.  Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.

Authors:  Sujatha Iyengar; Caixin Zhan; Jordan Lu; Robert Korngold; David H Schwartz
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-02       Impact factor: 5.742

3.  Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model.

Authors:  Jing Yuan; Han-yun Ren; Yong-jin Shi; Wei Liu
Journal:  Inflamm Res       Date:  2015-01-04       Impact factor: 4.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.